The new landscape of therapy for myelofibrosis

Krisstina Gowin, Robyn Emanuel, Holly Geyer, Ruben A. Mesa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm. The discovery of the JAK2 V617F mutation in 2005 has led to the rapid development of therapy specifically developed for afflicted MF patients. Indeed, the successful phase III studies of ruxolitinib demonstrating improved symptomatic burden, splenomegaly and survival led to the first approved myelofibrosis drug in the United States and Europe. Multiple additional JAK2 inhibitors are currently in or nearing phase III testing, including SAR302503 (fedratinib), SB1518 (pacritinib) and CYT387 (momelotinib), seeking to offer incremental benefits to ruxolitinib in regards to cytopenias or other disease features. In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. Multiple single agents strategies are ongoing with histone deacetylase inhibitors, hedgehog inhibitors and hypomethylation agents. Incremental advances are further sought, either in additive or synergistic fashion, from combination strategies of ruxolitinib with multiple different approaches ranging from allogeneic stem cell transplant to current therapies mitigating anemia and further impacting the bone marrow microenvironment or histology. Transitioning from a pre-2011 era devoid of approved MF therapies to one of multiple agents that target not only disease course but symptomatic burden has indeed changed the platform from which MF providers are able to launch individualized treatment plans. In this article, we discuss the diagnostic and therapeutic milestones achieved through MF research and review the emerging pharmacologic agents on the treatment horizon.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume8
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Primary Myelofibrosis
Therapeutics
Anemia
Histone Deacetylase Inhibitors
Immunomodulation
Splenomegaly
Histology
Stem Cells
Bone Marrow
Transplants
Mutation
Survival
Research
Pharmaceutical Preparations
INCB018424

Keywords

  • Hematologic malignancy
  • JAK2 inhibitors
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Ruxolitinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The new landscape of therapy for myelofibrosis. / Gowin, Krisstina; Emanuel, Robyn; Geyer, Holly; Mesa, Ruben A.

In: Current Hematologic Malignancy Reports, Vol. 8, No. 4, 12.2013, p. 325-332.

Research output: Contribution to journalArticle

Gowin, Krisstina ; Emanuel, Robyn ; Geyer, Holly ; Mesa, Ruben A. / The new landscape of therapy for myelofibrosis. In: Current Hematologic Malignancy Reports. 2013 ; Vol. 8, No. 4. pp. 325-332.
@article{797725c3038a4aa992bb0bdee415f7d9,
title = "The new landscape of therapy for myelofibrosis",
abstract = "The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm. The discovery of the JAK2 V617F mutation in 2005 has led to the rapid development of therapy specifically developed for afflicted MF patients. Indeed, the successful phase III studies of ruxolitinib demonstrating improved symptomatic burden, splenomegaly and survival led to the first approved myelofibrosis drug in the United States and Europe. Multiple additional JAK2 inhibitors are currently in or nearing phase III testing, including SAR302503 (fedratinib), SB1518 (pacritinib) and CYT387 (momelotinib), seeking to offer incremental benefits to ruxolitinib in regards to cytopenias or other disease features. In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. Multiple single agents strategies are ongoing with histone deacetylase inhibitors, hedgehog inhibitors and hypomethylation agents. Incremental advances are further sought, either in additive or synergistic fashion, from combination strategies of ruxolitinib with multiple different approaches ranging from allogeneic stem cell transplant to current therapies mitigating anemia and further impacting the bone marrow microenvironment or histology. Transitioning from a pre-2011 era devoid of approved MF therapies to one of multiple agents that target not only disease course but symptomatic burden has indeed changed the platform from which MF providers are able to launch individualized treatment plans. In this article, we discuss the diagnostic and therapeutic milestones achieved through MF research and review the emerging pharmacologic agents on the treatment horizon.",
keywords = "Hematologic malignancy, JAK2 inhibitors, Myelofibrosis, Myeloproliferative neoplasms, Ruxolitinib",
author = "Krisstina Gowin and Robyn Emanuel and Holly Geyer and Mesa, {Ruben A.}",
year = "2013",
month = "12",
doi = "10.1007/s11899-013-0178-x",
language = "English (US)",
volume = "8",
pages = "325--332",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "4",

}

TY - JOUR

T1 - The new landscape of therapy for myelofibrosis

AU - Gowin, Krisstina

AU - Emanuel, Robyn

AU - Geyer, Holly

AU - Mesa, Ruben A.

PY - 2013/12

Y1 - 2013/12

N2 - The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm. The discovery of the JAK2 V617F mutation in 2005 has led to the rapid development of therapy specifically developed for afflicted MF patients. Indeed, the successful phase III studies of ruxolitinib demonstrating improved symptomatic burden, splenomegaly and survival led to the first approved myelofibrosis drug in the United States and Europe. Multiple additional JAK2 inhibitors are currently in or nearing phase III testing, including SAR302503 (fedratinib), SB1518 (pacritinib) and CYT387 (momelotinib), seeking to offer incremental benefits to ruxolitinib in regards to cytopenias or other disease features. In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. Multiple single agents strategies are ongoing with histone deacetylase inhibitors, hedgehog inhibitors and hypomethylation agents. Incremental advances are further sought, either in additive or synergistic fashion, from combination strategies of ruxolitinib with multiple different approaches ranging from allogeneic stem cell transplant to current therapies mitigating anemia and further impacting the bone marrow microenvironment or histology. Transitioning from a pre-2011 era devoid of approved MF therapies to one of multiple agents that target not only disease course but symptomatic burden has indeed changed the platform from which MF providers are able to launch individualized treatment plans. In this article, we discuss the diagnostic and therapeutic milestones achieved through MF research and review the emerging pharmacologic agents on the treatment horizon.

AB - The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm. The discovery of the JAK2 V617F mutation in 2005 has led to the rapid development of therapy specifically developed for afflicted MF patients. Indeed, the successful phase III studies of ruxolitinib demonstrating improved symptomatic burden, splenomegaly and survival led to the first approved myelofibrosis drug in the United States and Europe. Multiple additional JAK2 inhibitors are currently in or nearing phase III testing, including SAR302503 (fedratinib), SB1518 (pacritinib) and CYT387 (momelotinib), seeking to offer incremental benefits to ruxolitinib in regards to cytopenias or other disease features. In parallel, phase III testing of pomalidomide is ongoing, with the goal of solidifying the role of immunomodulatory therapy in MF-associated anemia. Multiple single agents strategies are ongoing with histone deacetylase inhibitors, hedgehog inhibitors and hypomethylation agents. Incremental advances are further sought, either in additive or synergistic fashion, from combination strategies of ruxolitinib with multiple different approaches ranging from allogeneic stem cell transplant to current therapies mitigating anemia and further impacting the bone marrow microenvironment or histology. Transitioning from a pre-2011 era devoid of approved MF therapies to one of multiple agents that target not only disease course but symptomatic burden has indeed changed the platform from which MF providers are able to launch individualized treatment plans. In this article, we discuss the diagnostic and therapeutic milestones achieved through MF research and review the emerging pharmacologic agents on the treatment horizon.

KW - Hematologic malignancy

KW - JAK2 inhibitors

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=84890501821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890501821&partnerID=8YFLogxK

U2 - 10.1007/s11899-013-0178-x

DO - 10.1007/s11899-013-0178-x

M3 - Article

VL - 8

SP - 325

EP - 332

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 4

ER -